ChAdOx1 nCoV-19

A viral vector vaccine against SARS-CoV-2 developed by AstraZeneca. Its vector encodes the SARS-CoV-2 Spike protein.

Also Known As:

AZD1222; Covishield; AZD 1222; AstraZeneca, COVID-19 Vaccine; COVID 19 Vaccine AstraZeneca; COVID Vaccine, Oxford-AstraZeneca; COVID-19 Vaccine, ChAdOx1; COVID-19 Vaccine, Oxford-AstraZeneca; ChAdOx1 COVID 19 Vaccine; ChAdOx1 nCoV 19; Oxford AstraZeneca COVID 19 Vaccine; Oxford AstraZeneca COVID Vaccine; Vaccine, ChAdOx1 COVID-19; Vaccine, Oxford-AstraZeneca COVID; Vaccine, Oxford-AstraZeneca COVID-19; nCoV-19, ChAdOx1; AZD-1222; COVID-19 Vaccine AstraZeneca; ChAdOx1 COVID-19 Vaccine; Oxford-AstraZeneca COVID Vaccine; Oxford-AstraZeneca COVID-19 Vaccine; Vaxzevria

Networked: 924 relevant articles (40 outcomes, 85 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Complex Mixtures: 1906
- Biological Products
  - Vaccines: 124365
    - Synthetic Vaccines: 1073
      - Nucleic Acid-Based Vaccines: 108
        DNA Vaccines: 2674
        ChAdOx1 nCoV-19: 924
    - Viral Vaccines: 462
      - COVID-19 Vaccines: 7607
        ChAdOx1 nCoV-19: 924

Experts

1.	Lambe, Teresa: 21 articles (11/2022 - 01/2020)
2.	Gilbert, Sarah C: 16 articles (01/2022 - 01/2020)
3.	Greinacher, Andreas: 13 articles (01/2022 - 01/2021)
4.	Pollard, Andrew J: 12 articles (11/2022 - 01/2020)
5.	Thiele, Thomas: 11 articles (01/2022 - 01/2021)
6.	Bibi, Sagida: 10 articles (11/2022 - 01/2020)
7.	Voysey, Merryn: 9 articles (07/2022 - 01/2020)
8.	Warkentin, Theodore E: 9 articles (01/2022 - 01/2021)
9.	Aley, Parvinder K: 8 articles (11/2022 - 01/2020)
10.	Faust, Saul N: 8 articles (11/2022 - 01/2020)

Related Diseases

1.	COVID-19 01/01/2022 - "Covishield was effective in preventing SARS-CoV-2 infection and reducing disease severity in highly transmissible settings during the second wave of the pandemic driven by the Delta variant." 10/01/2023 - "The efficacy of the Oxford-AstraZeneca COVID-19 vaccine against symptomatic COVID-19 cases, various variants, ICU, and emergency admissions, and against deaths was high. " 05/01/2022 - "ChAdOx1 nCoV-19 was effective in reducing symptomatic COVID-19 in a socially vulnerable community in Brazil when Gamma and Delta were the predominant variants circulating." 10/01/2023 - "The efficacy of the Oxford-AstraZeneca COVID-19 vaccine against symptomatic COVID-19 cases after the first dose was 60.59% (p=0.00001) and after the second dose was 66.84% (p=0.00001). " 08/01/2023 - "Primary-series AZD1222 vaccination confers protection against COVID-19 hospitalisation with enduring levels of VE through ≥6 months. "
2.	Infections 05/10/2021 - "In preclinical trials, the efficacy of ChAdOx1 nCoV-19 against SARS-CoV-2 challenge was evaluated in a ferret model of infection. " 01/01/2023 - "We compared SARS-CoV-2 spike-specific Fc functions, binding, and neutralization in PLWH and people without HIV (PWOH) during acute infection (without prior vaccination) with either the D614G or Beta variants of SARS-CoV-2, or vaccination with ChAdOx1 nCoV-19. " 01/01/2023 - "The Omicron B.1.1.529 variant increased severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in doubly vaccinated individuals, particularly in the Oxford-AstraZeneca COVID-19 vaccine (ChAdOx1) recipients. " 10/17/2022 - "Waning titres post second dose indicates the need for booster dosing after AZD1222 in the African setting despite hybrid immunity from previous infection." 01/01/2022 - "SARS-CoV-2 Antibody Response After ChAdOx1 nCoV-19 Vaccination in Persons With Previous SARS-CoV-1 Infection."
3.	Pneumonia (Pneumonitis) 10/07/2021 - "We previously showed protection against SARS-CoV-2 disease and pneumonia in hamsters vaccinated with a single dose of ChAdOx1 nCoV-19. " 06/30/2021 - "We previously showed protection against SARS-CoV-2 disease and pneumonia in hamsters vaccinated with a single dose of ChAdOx1 nCoV-19. " 01/01/2021 - "We demonstrate in rhesus macaques the lung pathology caused by SARS-CoV-2 mediated pneumonia is reduced by prior vaccination with ChAdOx1 nCoV-19 which induced neutralising antibody responses after a single intramuscular administration. " 05/13/2020 - "ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques." 01/01/2022 - "The purpose of the current study is to compare the severity of COVID-19 pneumonia using CT-SS in COVID-19-positive vaccinated (Covishield/Oxford-AstraZeneca) and non-vaccinated individuals and to compare the final outcome wherever possible. "
4.	Thrombocytopenia (Thrombopenia) 10/01/2023 - "A few concerns were raised concerning the Covishield vaccination related to thrombotic thrombocytopenia. " 01/01/2023 - "The background incidence of CVST combined with thrombocytopenia was minuscule compared to the incidence during the weeks following the ChAdOx1 nCov-19 vaccination. " 01/01/2023 - "We found 2 episodes of CVST with thrombocytopenia within 28 days of the first ChAdOx1 nCov-19 vaccination (among 200,397 vaccinated, aged 16 or above). " 03/01/2022 - "Histological and immunohistochemical findings in a fatal case of thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination." 01/01/2022 - "Thrombocytopenia and splenic platelet-directed immune responses after IV ChAdOx1 nCov-19 administration."
5.	Venous Thromboembolism 12/01/2021 - "Venous Thromboembolism and Mild Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination." 08/14/2021 - "While generally safe and effective, rare cases of venous thromboembolism (VTE) have been reported after two adenovirus-based vaccines, the AstraZeneca ChAdOx1 nCoV-19 vaccine and the Janssen Ad.26.COV2.S vaccine, as well as after the Pfizer-BioNTech BNT162b2 mRNA vaccine. " 01/01/2021 - "The study found increased risk of thrombocytopenia after ChAdOx1 nCoV-19 vaccination (incidence rate ratio 1.33, 95% confidence interval 1.19 to 1.47 at 8-14 days) and after a positive SARS-CoV-2 test (5.27, 4.34 to 6.40 at 8-14 days); increased risk of venous thromboembolism after ChAdOx1 nCoV-19 vaccination (1.10, 1.02 to 1.18 at 8-14 days) and after SARS-CoV-2 infection (13.86, 12.76 to 15.05 at 8-14 days); and increased risk of arterial thromboembolism after BNT162b2 mRNA vaccination (1.06, 1.01 to 1.10 at 15-21 days) and after SARS-CoV-2 infection (2.02, 1.82 to 2.24 at 15-21 days). " 01/01/2021 - "The primary outcomes were hospital admission or death associated with thrombocytopenia, venous thromboembolism, and arterial thromboembolism within 28 days of three exposures: first dose of the ChAdOx1 nCoV-19 vaccine; first dose of the BNT162b2 mRNA vaccine; and a SARS-CoV-2 positive test. "

Related Drugs and Biologics

1.	Vaccines
2.	BNT162 Vaccine
3.	sinovac COVID-19 vaccine
4.	ChAdOx1 nCoV-19
5.	mRNA Vaccines
6.	BBV152 COVID-19 vaccine
7.	2019-nCoV Vaccine mRNA-1273
8.	Immunoglobulin G (IgG)
9.	Ad26COVS1
10.	Messenger RNA (mRNA)

Related Therapies and Procedures

1.	Renal Dialysis (Hemodialysis)
2.	Renal Replacement Therapy (Therapies, Renal Replacement)
3.	Penetrating Keratoplasty
4.	Heart Transplantation (Grafting, Heart)
5.	Therapeutics